Safety of Arthritis Drugs, Day 3. Part 4

This is the last day of a joint meeting of the FDA’s Arthritis and Drug Safety and Risk Management Advisory Committees. At the… read more

This is the last day of a joint meeting of the FDA’s Arthritis and Drug Safety and Risk Management Advisory Committees. At the end of the three-day forum the 32-member panel had recommended that arthritis drugs Celebrex and Bextra stay on the market with restrictions. This portion included the 17-15 vote that Vioxx should stay on the U.S. market, and other votes about restrictions on Vioxx. 

Dr. Wood is chairman of the Arthritis Advisory Committee, Drug Safety and Risk Management Committee. close

Javascript must be enabled in order to access C-SPAN videos.

People in this video

  • Abramson, Steven Chairman New York University Medical School->Rheumatology
  • Bathon, Joan Professor Johns Hopkins University->Medical School
More People

Hosting Organization

More Videos From

Safety of Arthritis Drugs, Day 3,

More Videos
More information about

Safety of Arthritis Drugs, Day 3. Part 4

57 Views
Program ID:
185600-4
Category:
Public Affairs Event
Format:
Forum
Location:
Gaithersburg, Maryland, United States
First Aired:
Feb 19, 2005
Last Aired:
Feb 25, 2005

Airing Details

  • Feb 19, 2005 | 3:02pm EST | C-SPAN 1
  • Feb 25, 2005 | 1:52pm EST | C-SPAN 2